modelL01BB04

Diagram of L01BB04

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Cladribine
ATC code:L01BB04
route:oral
compartments:2
dosage:10mg
volume of distribution:480L
clearance:28.7L/h
other parameters in model implementation

Cladribine is a purine nucleoside analogue used primarily as an antineoplastic agent for the treatment of hematological malignancies such as hairy cell leukemia and multiple sclerosis. Cladribine is approved for use in relapsing forms of multiple sclerosis and has demonstrated efficacy as an immunomodulatory and cytotoxic agent due to its selective cytotoxicity for lymphocytes.

Pharmacokinetics

Pharmacokinetic parameters in adult patients with multiple sclerosis following oral administration

References

  1. Savic, RM, et al., & Karlsson, MO (2017). Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. Clinical pharmacokinetics 56(10) 1245–1253. DOI:10.1007/s40262-017-0516-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28255849

  2. Lindemalm, S, et al., & Albertioni, F (2005). Application of population pharmacokinetics to cladribine. BMC pharmacology 5 4–None. DOI:10.1186/1471-2210-5-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15757511

  3. Meuth, SG, et al., & Hartung, HP (2018). [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]. Der Nervenarzt 89(8) 895–907. DOI:10.1007/s00115-018-0498-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29523912

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)